Get to know our clinical trials

Clinical trial to determine the efficacy and safety of BIIB122 in participants with Parkinson's disease.

THE MAIN OBJECTIVE OF THIS CLINICAL TRIAL IS TO SEE IF THE CLINICAL TRIAL DRUG WORKS IN PEOPLE WHO HAVE EARLY-STAGE PD, HOW SAFE IT IS IN TERMS OF MEDICAL PROBLEMS KNOWN AS ¿SIDE EFFECTS,¿ AND HOW THE BODY HANDLES TAKING IT (TOLERABILITY).

Status
In recruitment
headquarters
Pamplona
Early phase

Technical Summary

  • PHASE IIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF BIIB122 IN PARTICIPANTS WITH PARKINSON'S DISEASE.
  • Code EudraCT: 2021-004849-20
  • Protocol number: 283PD201
  • Promoter: Biogen Idec Iberica, S.L.

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs
Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.